Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
April 25 2022 - 8:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a
commercial-stage biopharmaceutical company focused on in-licensing,
developing, and commercializing novel medicines for patients living
with rare diseases, today announced that it will release its
first-quarter 2022 financial results after market close on
Tuesday, May 10, 2022.
Catalyst's management team will host a
conference call and webcast the following morning, Wednesday, May
11, 2022, at 8:30 AM ET, to discuss the Company's financial
results and provide a corporate update.
Conference Call & Webcast
Details
Date/Time: |
May 11, 2022, at 8:30 AM ET |
US/Canada Dial-in Number: |
(877) 407-8912 |
International Dial-in Number: |
(201) 689-8059 |
A webcast and accompanying materials will be
accessible under the Investors section on the Company's website
at www.catalystpharma.com. A replay of the webcast will be
available on the Catalyst website for 30 days following the date of
the event.
About Catalyst
PharmaceuticalsCatalyst Pharmaceuticals is a
commercial-stage biopharmaceutical company focused on in-licensing,
developing, and commercializing novel medicines for patients living
with rare diseases. With exceptional patient focus, Catalyst is
committed to developing a robust pipeline of cutting-edge,
best-in-class medicines for rare diseases. Catalyst's New Drug
Application for FIRDAPSE® (amifampridine) Tablets 10 mg for
the treatment of adults with Lambert-Eaton myasthenic syndrome
("LEMS") was approved in 2018 by the U.S. Food & Drug
Administration ("FDA"), and FIRDAPSE is commercially available
in the United States as a treatment for adults with LEMS.
Further, Canada's national healthcare regulatory
agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS.
Forward-Looking StatementsThis
press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which
may cause Catalyst's actual results in future periods to differ
materially from forecasted results. A number of factors, including
those factors described in Catalyst's Annual Report on Form 10-K
for the fiscal year 2021 and its other filings with the U.S.
Securities and Exchange Commission ("SEC"), could adversely
affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website, or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Media Contact
David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Investor Contact
Mary Coleman
Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024